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Introduction
Aging is the dominant risk factor for most chronic diseases that afflict people in industrialized societies. 
There is now ample evidence, in mice, that the process of  aging can be delayed or retarded by low-calorie 
diets (1–5), by natural or engineered mutations in any of  several genes that modify growth hormone and 
IGF-1 signals (6, 7), and, more recently, by drugs added to food (8). Each of  these approaches has been 
shown to extend life span and also to delay multiple forms of  late-life illness, including both neoplastic and 
degenerative diseases. Identification of  new drugs that extend mammalian life span is of  great interest from 
at least 2 perspectives. First, elucidating the mechanism of  action of  such agents will provide new insights 
Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and 
kidney diseases. It also inhibits the sodium glucose transporter 2 by blocking renal reuptake and 
intestinal absorption of glucose. In the context of the mouse Interventions Testing Program, 
genetically heterogeneous mice were given chow containing Cana at 180 ppm at 7 months of age 
until their death. Cana extended median survival of male mice by 14%. Cana also increased by 9% 
the age for 90th percentile survival, with parallel effects seen at each of 3 test sites. Neither the 
distribution of inferred cause of death nor incidental pathology findings at end-of-life necropsies 
were altered by Cana. Moreover, although no life span benefits were seen in female mice, Cana led 
to lower fasting glucose and improved glucose tolerance in both sexes, diminishing fat mass in 
females only. Therefore, the life span benefit of Cana is likely to reflect blunting of peak glucose 
levels, because similar longevity effects are seen in male mice given acarbose, a diabetes drug that 
blocks glucose surges through a distinct mechanism, i.e., slowing breakdown of carbohydrate in 
the intestine. Interventions that control daily peak glucose levels deserve attention as possible 
preventive medicines to protect from a wide range of late-life neoplastic and degenerative diseases.
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into the biology of  the aging process and into the links between aging and multiple forms of  late-life diseas-
es. Second, these drugs may provide a starting point for development of  antiaging interventions in humans.
The Interventions Testing Program (ITP), supported by the National Institute on Aging (NIA), tests 
the effects of  drugs on mouse life span (http://www.nia.nih.gov/research/dab/interventions-testing-pro-
gram-itp) (9, 10). ITP studies use annual cohorts of  genetically heterogeneous mice (UM-HET3) equally 
distributed among 3 testing sites. Six compounds have thus far produced significant extension of  life span 
in ITP studies in 1 or both sexes: rapamycin (11–13), 17α-estradiol (17aE2) (14, 15), nordihydroguaiaretic 
acid (NDGA) (15, 16), Protandim (14), glycine (17), and acarbose (15, 18). In a previous study, a seventh 
agent, aspirin, produced significant life span extension in male mice (16), but failed to show a benefit at 2 
higher doses in a follow-up study (unpublished data).
The ITP experiment with Cana was motivated in part by our results using acarbose, a drug used in 
the treatment of  type 2 diabetes (T2DM). Acarbose functions by inhibiting the breakdown of  complex 
carbohydrates in the small intestine, thereby slowing the pace of  glucose uptake and blunting the normal 
postprandial spike in blood glucose levels. In humans, acarbose treatment reduces glycated hemoglobin 
A1c (HbA1c) levels (19), although this effect was not seen in the ITP acarbose-treated mice (15). Acarbose, 
started at 4 months of  age, led to a 22% increase in median life span in UM-HET3 male mice, and a signifi-
cant but much smaller 5% increase in female mice (15). A test for effects on maximum life span (proportion 
alive at the 90th percentile) was significant in both sexes. When initiated at 16 months, acarbose leads to 
significant life span extension in male mice but a smaller effect in female mice (14). Acarbose-treated male 
mice also show a delay in age-dependent pathology in multiple systems, including inflammatory changes 
in the hypothalamus (20). Taken together, these results suggest that blunting of  postprandial glucose peaks 
could delay aging and its consequences, including the illnesses that lead to death in mice. However, they do 
not exclude other possible mechanisms for acarbose action.
These results prompted us to consider whether other drugs that inhibit surges in postprandial blood 
glucose levels might also exert beneficial effects on longevity. Cana is an FDA-approved diabetes drug 
that acts primarily by inhibition of  the sodium glucose transporter 2 (SGLT2) in the proximal tubule of  
the kidney (21). In nondiabetic individuals, SGLT2 is responsible for up to 97% of  the reabsorption of  
the 160–180 g of  glucose filtered by the kidney per day. To a lesser extent, Cana also inhibits SGLT1, a 
related glucose transporter with broader distribution, expressed in the small intestine, kidney, and heart, 
among other tissues. In a large group of  patients with T2DM and elevated cardiovascular risk, Cana 
reduced death from cardiovascular causes, as well as nonfatal strokes, myocardial infarction, and heart 
failure (22). In patients with T2DM with kidney disease, Cana greatly reduced the risk of  progression 
to kidney failure as well as the risk of  cardiovascular events. Cana, like other SGLT2 inhibitors, reduces 
fasting blood glucose, HbA1c levels, and body weight, while modestly increasing blood ketone levels 
(23). Like acarbose, Cana suppresses the postprandial glucose surge (24, 25). The cardioprotective effects 
of  SGLT2 inhibitors may be independent, at least partly, of  their glycemic effects (26). Moreover, studies 
in mice have documented effects of  Cana treatment on pathways relevant for life span: mTOR signaling, 
AMPK signaling, and FGF21 levels (27). In view of  our previous results using acarbose, and the evi-
dence for beneficial effects of  SGLT2 inhibitors in humans, we conducted a test of  the hypothesis that 
Cana would extend mouse life span.
Results
Survival. In the context of  the NIA ITP, groups of  genetically heterogeneous (UM-HET3) mice born in 
2016 were placed on a chow diet containing Cana at 180 ppm at the age of  7 months and followed for 
survival. Approximately 50 male mice and 50 female mice were exposed to Cana at each of  the 3 test sites 
(The Jackson Laboratory [TJL], University of  Michigan [UM], and University of  Texas Health Science 
Center at San Antonio [UT]). Each site enrolled approximately 100 male and 100 female control mice, 
which also served as the control group for the other drugs tested in 2016. Date of  death was recorded, 
and mice euthanized for humane reasons were considered to have died on the date of  euthanasia. Figure 
1 shows the survival curves for each combination of  sex and site as well as the survival data pooled across 
all 3 sites. Table 1 shows the summary statistics for each site and for the pool. The prespecified primary 
outcome was the log-rank test for the pooled data set, calculated separately for each sex, and stratified for 
site within sex. For the C2016 cohort, there were no significant differences (log-rank test) among the 3 test 
sites for survival of  male or female controls.
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Figure 1. Survival curves for Cana-treated and sex-matched mice. (A and B) Data pooled across sites. (C–H) Site-specific results. Female mice 
are shown on the left, and male mice are shown on the right. P values show results of log-rank tests, not adjusted for multiple comparisons, with 
site as covariate for the pooled data sets (top row). There were no remaining live mice at the time of analysis. The number of mice in each group is 
included in the count column of Table 1.
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For male mice, Cana increased median survival age by 14%; the log-rank test yielded P < 0.001. The 
log-rank test was also calculated for each site separately, and despite much lower statistical power, survival 
was improved at each site, with P < 0.001 at TJL and UM and P = 0.06 at UT. Age at the 90th percentile 
survival point was taken as a prespecified index of  long-term (“maximal”) survival, and this increased by 
9% in the pooled male mice, with site-specific values of  15%, 9%, and 3% for TJL, UM, and UT, respective-
ly. The Fisher’s exact test version of  the Wang-Allison (WA) test (28) was used to evaluate the likelihood 
that the drug modified the proportion of  survivors at the 90th percentile; the calculated P value, P < 0.001, 
suggests that Cana increases maximum survival in male mice. The WA statistic was significant at TJL and 
UM, but not at UT. None of  these indices of  improved survival were noted in female mice, for which the 
median survival age increased by only 1% (site-specific changes of  3%, 4%, and –4%), and age at the 90th 
percentile survival was increased by 1% (NS).
We measured Cana levels in plasma, brain, and liver of  mice aged 22 months, after exposure to Cana 
from 7 months of  age. Plasma of  female mice had a mean Cana concentration of  13.2 μg/mL (SEM = 0.9, 
N = 5), significantly higher than plasma levels of  male mice (3.6 ± 0.6, N = 8; P < 0.001). Figure 2 shows 
that Cana levels in brain and in kidney were also significantly higher (P < 0.001) in female mice than in 
male mice. Plasma levels in brain and kidney were well correlated with levels in female mice but not in male 
mice. Plasma levels in young adults exposed to Cana for 8 weeks were lower than in mice exposed for 15 
months but showed a similar sexual dimorphism, with values ranging from 2.12 to 3.53 μg/mL (N = 4) in 
female mice and from 0.36 to 0.86 μg/mL (N = 3) in male mice (P = 0.003 for the sex effect). These values 
are in the range of  those reported for humans administered this drug (29). Thus, the absence of  a survival 
benefit in Cana-treated female mice cannot be attributed to lower circulating levels of  the drug. Husbandry 
technicians noted much higher urine output in the Cana-treated mice of  both sexes throughout the study.
Weight. Cana limits weight gain in both sexes, as shown in Figure 3. In female mice, the effect on 
weight is dramatic (17%–19%) and statistically significant (P < 0.0001) at each age after initiation of  drug 
treatment at 7 months. Cana-treated male mice are 5%–8% lighter than controls at ages 12 and 18 months 
(P < 0.0002). Mean weight of  control male mice declines between 18 and 24 months, presumably related 
to onset of  late-life illness and/or death of  the heaviest male mice, but this effect is blunted in Cana-treated 
mice. The male-specific alteration in life span is apparently not attributable to a male-specific blockage of  
midlife weight gain.
HbA1c levels. HbA1c was evaluated in whole blood of  48 female and 45 male mice, after exposure to 
Cana for 7–8 months starting at 7 months of  age, with samples taken at all 3 test sites. There was no effect 
of  Cana on HbA1c levels (control male mice 3.8%, Cana-treated male mice 3.7; control female mice 3.5, 
Table 1. Life span statistics for Cana and control mice — pooled and site-specific results
Rx Group Sex Count Median (d) Percentage 
change in 
median 




change in 90th 
percentile
WA P value
Cont_16 Pool M 303 787 1047
Cana Pool M 156 897 14 < 0.0001 1143 9 < 0.0001
Cont_16 TJL M 102 749 1005
Cana TJL M 54 880 17 0.001 1159 15 0.003
Cont_16 UM M 102 814 1071
Cana UM M 51 946 16 0.001 1170 9 0.001
Cont_16 UT M 99 799 1064
Cana UT M 51 866 8 0.060 1099 3 0.39
Cont_16 Pool F 304 874 1050
Cana Pool F 136 886 1 0.512 1059 1 0.50
Cont_16 TJL F 96 883 1057
Cana TJL F 48 912 3 0.173 1097 4 0.26
Cont_16 UM F 92 858 1034
Cana UM F 44 897 4 0.263 1076 4 0.38
Cont_16 UT F 116 882 1058
Cana UT F 44 849 –4 0.142 1003 –5 0.56
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Cana-treated female mice 3.5), although the difference between sexes was significant at P < 0.0001 in a 
2-way ANOVA. This result is consistent with our previous data on HbA1c in acarbose-treated mice (15), 
although Cana diminishes HbA1c in patients with diabetes (22).
Body composition and glucose homeostasis. UM-HET3 mice born at UM received Cana or control chow 
from the age of  7 months and were then transferred at 20–22 months of  age to the Sadagurski laboratory 
at Wayne State University for metabolic testing and evaluation of  body composition. Figure 4 shows that 
Cana did not alter total mass, lean mass, or fat mass in male mice but led to a significant (18%) decline in 
total mass and a 41% decline in fat mass in female mice. Glucose, measured after a 3- to 4-hour fast, was 
lower in the Cana-treated mice than in controls for both sexes. An i.p. glucose tolerance test showed signifi-
cantly better responses in Cana-treated mice of  both sexes.
Cause of  death. All mice dying at ages above 600 days were fixed, and a random sample (10 male mice 
and 10 female mice from each site in each of  2 drug conditions) was sent for evaluation to the University of  
Washington Geropathology Research Program with no information regarding Cana status. The mean age 
of  Cana-treated mice was 873 days (male mice) or 892 days (female mice), and the values for control mice 
were 845 and 857 for male and female mice, respectively. Each case was evaluated in-house by the same 
board-certified veterinary pathologist, who attempted to infer the cause(s) of  death, i.e., the lesion(s) that 
appeared most likely to have led either to the death of  the mouse or the decision to euthanize the mouse for 
humane reasons at the end of  life.
Table 2 shows the distribution of  inferred causes of  death (CODs) among the mice. Statistical power 
is poor, because most individual diagnoses appeared in 7 or fewer of  the 120 cases. The most common 
lethal lesion was hematopoietic neoplasia (HPN), a collection of  hematopoietic neoplastic diseases, includ-
ing lymphoma and histiocytic sarcoma, that are difficult to distinguish without special stains or molecular 
characterization. HPN was noted in 18 of  60 Cana-treated mice and in 16 of  60 controls. For most lesions, 
there were no effects of  site (although as noted with very low statistical power), but HPN as a (COD) was 
more common at TJL (16 of  28 cases in which a COD could be inferred) than at UM and UT (18 of  70 non-
autolyzed cases, P = 0.003). None of  the classes of  lethal illness shows a statistically significant difference 
between treated and control mice. For Cana-treated mice, there were 45 cases for which a single COD could 
Figure 2. Cana levels in plasma, brain, and kidney of 22-month-old mice exposed to Cana from 7 months of age. 
Scatterplots show kidney levels of Cana (top) or brain levels (bottom) versus plasma levels. Each symbol refers to 1 
mouse (5 female mice and 8 male mice were included).
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be assigned; this excludes the 10 cases where multiple lesions were deemed contributory and the 5 cases with 
advanced autolysis. Of  these 45 mice, 34 (76%) died of  some form of  neoplastic disease. Similarly, 36 of  the 
44 evaluable control cases (82%) died of  neoplasia (P = 0.12 for contrast with Cana-treated mice.)
Incidental pathology at end of  life. In addition to attempting to infer a likely COD, the pathologist record-
ed presence or absence of  lesions in multiple tissues and assigned a grade of  severity for a separate set 
of  lesions (see Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.140019DS1). Supplemental Table 1 shows 21 lesions (in adrenal, atrium, lung, 
heart, liver, kidney, mammary gland, thalamus, pancreas, spleen, and thyroid) that were scored as present or 
absent, with P values showing results of  the Fisher’s exact test comparing Cana to control mice. Drug treat-
ment had no significant effects on frequency of  any of  these lesions. Supplemental Table 2 shows 14 lesions 
that were graded on scales of  0–2 or 0–4, depending on the lesion. The P value shown reflects the 2-sided 
Student’s t test contrasting treated and control mice. Only 1 form of  pathology met the criteria for statistical 
significance: the mean level of  liver telangiectasia/angiectasis was 0.41 for Cana and 0.09 for control mice 
(P = 0.01). Since this lesion is graded on a scale of  1–4, with a score of  1 corresponding to minimal change, 
it seems unlikely that this drug effect has any clinical implication. With that exception, the data suggest that 
Cana-treated mice show similar incidence and severity of  most forms of  end-of-life pathology.
Discussion
Interventions, whether diets, mutations, or drugs, that slow aging and postpone multiple forms of  late-
life illness provide valuable tools for investigation of  the cellular and molecular mechanisms for aging, as 
well as hints as to where those tools might most usefully be applied. Among the 7 ITP-tested drugs that 
have shown significant longevity benefit, Cana, acarbose, 17aE2, and rapamycin have the largest effect on 
Figure 3. Mean weights for Cana and control mice, ages 6–24 months. Values are mean levels for live mice, separately 
for each sex, pooled across sites. Cana treatment was initiated at 7 months. *P < 0.0002 for drug effect at ages 12–24 
for female mice and 12–18 for male mice. N declined with age from 151–116 for Cana-treated male mice and from 136–107 
for Cana-treated female mice, with approximately 2-fold higher numbers of control mice.
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median life span, and each of  these also has a significant effect on our measure of  maximum life span (28), 
in one or both sexes. Surprisingly, acarbose, 17aE2, and rapamycin can each produce significant life span 
extension even when started at ages 60%–70% of  the median survival age of  controls, i.e., 16–20 months 
of  age (13, 14) (unpublished observations for 17aE2). Life span studies in which Cana is initiated at old-
er ages are now under way at each ITP site. Terminal (end-of-life) necropsies for each of  these 4 drugs, 
including the data on Cana shown here, lead to the same conclusion: the spectrum of  lethal and nonlethal 
late-life illnesses is not changed in quality or severity, even though the treated mice are older at time of  
death. Although this conclusion is limited by the low statistical power of  small case series, the implication 
is that the drugs extend healthy life span, i.e., produce longer life span by delaying the onset or progression 
of  the diseases most likely to lead to death or terminal morbidity, most of  which are neoplastic disease in 
UM-HET3 and most other mouse stocks. A comprehensive series of  cross-sectional necropsies of  rapamy-
cin-treated mice (30), euthanized at 22 months of  age, supported this inference by showing 9 varieties of  
age-dependent lesions, in multiple organs, the incidence of  which was reduced by rapamycin.
The results of  these studies show an unexpected degree of  sexual dimorphism. The percentage benefit 
of  rapamycin, at each tested dose, is higher in female mice than in male mice, although this seems likely 
to reflect the higher blood rapamycin levels, in female mice, at matched doses in food (11). It is unclear 
which sex would show preferential benefit at fixed blood levels of  rapamycin. Acarbose, both in the original 
report and in an independent follow-up study (15, 18), led to significant life span extension in both sexes, 
but with much larger effects in male mice. The nonfeminizing steroid 17aE2, in contrast, produced benefits 
only in male mice; 17aE2-treated male mice lived significantly longer than female mice whether or not the 
female mice had received this agent (14, 15). Two other tested drugs also produced significant life span 
benefits in male mice only. NDGA, an antioxidant with antiinflammatory properties, led to male-specific 
life span increase of  up to 12% (P = 0.006 by log-rank test), although without a significant increase in max-
imal life span; the benefit, and its limitation to male mice, was replicated in an independent study (14–16). 
Figure 4. Body composition and glucose homeostasis in Cana versus control mice. Each symbol represents a different 
mouse, with mean ± SEM also shown. Mice were given Cana from 7 months of age, and tested when 20–22 months old. 
(A–F, I, and J) The body composition and glucose tolerance data were obtained using 8–11 mice of each sex for each group, 
and (G and H) the fasting glucose data were obtained from 6 mice of each sex for each group. The glucose tolerance test 
data show results for 5 male mice and 6 female mice in each treatment group. *P < 0.05, **P < 0.01, ****P < 0.0001.
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Protandim, a mixture of  botanical extracts known to activate the Nrf2 stress-response pathway, also led to 
increased life span in male mice only (14). Only one other tested agent, the amino acid glycine, produced 
significant life span extension in both male and female mice, and the effect, though seen at each of  the 3 
ITP test sites, was quite small, yielding less than a 5% increase in median longevity (17). Effects of  acar-
bose, including an increase in glucose tolerance and mTORC2 function (31) and a reduction of  subscapular 
fat depots (18), were seen principally in male mice, and the effects of  17aE2 on metabolite profiles, glucose 
control, grip strength, and rotarod performance were also male-specific (32). Both acarbose and 17aE2 
reduce mid-life hypothalamic inflammation in male mice only (20). More work will be needed to work out 
the molecular and physiological explanation(s) for these sex-specific effects, but it is notable that at least 
some of  these effects are blocked by castration of  young adult male mice before the initiation of  treatment 
by acarbose or 17aE2 (31, 32), suggesting that levels of  male hormones, even in postpubertal adults, sensi-
tize mice to life span extension by these drugs.
Cana and acarbose each reduce serum glucose in mice, or people, who have recently consumed a car-
bohydrate-rich meal, but they do so through partly different mechanisms. In addition to potently inhibiting 
SGLT2, Cana also reduces glucose uptake via SGLT1 in the small intestine and kidney, albeit with less 
potency than its effect on SGLT2 (33, 34). Physiologically, Cana suppresses glucose reuptake in the kidney, 
as well as delaying glucose absorption in the small intestine (21). Acarbose inhibits breakdown of  polysac-
charides to absorbable monosaccharides in the intestine. These observations thus suggest strongly that the 
life span benefits of  each drug, and presumably the other benefits already shown in acarbose-treated mice, 
are a consequence of  lower maximal postprandial glucose levels. Metabolically, Cana and other SGLT2 
inhibitors (SGLT2i) lower body weight, HbA1c, and peak glucose levels in humans; improve insulin resis-
tance; increase serum ketones; enhance fatty acid oxidation; and elevate β cell function (21). In our mice, 
Cana led to lower fasting glucose and improved glucose tolerance in both sexes, and to lower fat mass in 
female mice only. Neither Cana nor acarbose, at the doses used by the ITP, seems to diminish HbA1c, 
suggesting that the life span and health benefits in mice may depend more on peak glucose levels than on 
average glucose levels integrated over the day. UM-HET3 mice do not spontaneously develop diabetes, and 
Cana reduces the elevated HbA1c levels observed in diabetic rats and mice (33, 35, 36). Thus, it is possible 
that our studies in UM-HET3 mice underestimate the potential health benefits of  long-term Cana treat-
ment in humans, in which glucose intolerance and frank diabetes are common features of  aging (37). The 
dramatic effects on weight shown in both male and female mice in Figure 3, and the data on fasting glucose 
and glucose tolerance included in Figure 4, show that Cana has strong effects on fuel use and metabolic 
partitioning in both sexes. However, additional studies will be needed to evaluate sex-specific modulations 
of  relevant factors, particularly including insulin production and sensitivity, fat cell homeostasis and adipo-
kine production, and hypothalamic and gastrointestinal circuits that modulate appetite and satiety. Nota-
bly, no major sex-specific effects of  Cana have been reported in clinical trials documenting its beneficial 
Table 2. Inferred causes of death in Cana and control mice
Cases
Inferred cause Cana Control Total
Hematopoietic neoplasia 18 16 34
Hemangiosarcoma 2 3 5
Liver neoplasia 3 4 7
Lung carcinoma 2 5 7
Neoplastic, other 9 8 17
Atrial thrombosis 5 2 7
Nonneoplastic, other 6 6 12
Multiple or unknown 10 11 21
Autolysis 5 5 10
Total 60 60 120
The “Neoplastic, other” category includes bone tumor (N = 2), mammary adenocarcinoma (3), renal carcinoma (1), 
metastatic carcinoma of unknown primary site (4), unclassifiable neoplasia (6), and pituitary adenoma (1). The 
“Nonneoplastic, other” category includes endometritis (1), nephropathy (2), urinary tract obstruction (3), amyloidosis 
(2), and pyelonephritis (4).
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effects in humans. However, our results are consistent with prior studies of  long-term Cana administration 
in rats (38). In these studies, Cana, in a dose-dependent manner, extended rat life span, with a much greater 
effect observed in male mice than in female mice. As with other ITP drugs for which sexual dimorphic 
benefits are observed, the basis for the sex specificity of  Cana on rodent life span remains unclear.
The end-of-life necropsy data for Cana-treated mice are consistent with previous findings on mice in 
which their life span was extended by 17aE2, acarbose, and rapamycin (12, 15). Specifically, the spectrum 
of  lethal and nonlethal lesions, with a few exceptions, is similar between control and drug-treated mice, but 
delayed in timing. We see 2 complementary implications, one drawn from pathophysiology and the other 
from biogerontology. From the first perspective, our results justify follow-up studies to learn more about 
how these drug-induced changes, such as the blunting of  peak glucose levels that accompanies acarbose 
and Cana treatment, might delay or decelerate the most frequent forms of  age-related illnesses, such as 
neoplasms of  many tissues and the wide range of  degenerative diseases seen in mice and humans, and can 
begin to test dietary and pharmacological interventions aimed at controlling glucose peaks. In parallel, 
researchers focused on questions in the basic biology of  aging can use these drugs as experimental tools for 
testing hypotheses about how aging might be linked upstream to glucose or mTOR or steroid balance, and 
downstream to disability and dysfunction.
Cana and other SGLT2i show a wide spectrum of  beneficial effects in humans and rodent models, 
which in principle could contribute to extension of  mouse life span by Cana. The basis for these protective 
effects is not completely understood, and may not directly reflect the effects of  Cana on glucose homeostasis. 
For example, Cana reduces systolic and diastolic blood pressure, fatal and nonfatal cardiovascular events, 
and hospitalization for heart failure (22). The potent cardioprotective effects of  Cana and other SGLT2i are 
not observed to the same degree in patients treated with other, comparably potent, glucose-lowering agents, 
suggesting that pleiotropic effects of  SGLT2i may be involved (23). Since most UM-HET3 mice die of  neo-
plastic disease, the effects of  Cana on cancer may be particularly relevant for its ability to extend mouse life 
span. In preclinical studies, Cana administered at high doses to rats increased the frequency of  adrenal and 
renal tubular tumors, and induced Leydig cell hyperplasia and adenomas at all doses in male mice (38). In a 
recent meta-analysis, however, SGTL2i use in humans was not associated with an overall increased cancer 
risk, and Cana specifically was associated with a reduced risk of  gastrointestinal cancer (39).
Hypothetically, Cana might reduce mortality associated with neoplasia in mice by modulating glucose 
metabolism in tumor cells. The metabolic requirements of rapidly dividing cancer cells are quite distinct from 
those of normal cells, most of which are ordinarily nonmitotic. In contrast, cancer cells must constantly gen-
erate large quantities of new biomolecules for macromolecular synthesis and cell replication. For most can-
cer types, glucose, and particularly glycolytic intermediates derived from it, represents a critically important 
fuel (40). SGLT1 and SGLT2 are functionally expressed on human prostate and pancreas cancers, and Cana 
treatment of a pancreas cancer xenograft potentiated the effects of genotoxic chemotherapy (41). Cana inhibits 
growth of SGLT2-expressing hepatocellular cancer xenografts via inhibition of glycolysis and suppression of  
tumor angiogenesis (42), and by reducing β-catenin expression (43). In a mouse model of nonalcoholic ste-
atohepatitis-induced hepatocellular carcinoma, Cana reduced hepatic triglyceride accumulation, inflammation, 
and tumorigenesis (44). Cana has also been proposed to suppress growth of prostate and lung cancer cells via a 
non-SGLT1/2-dependent mechanism involving inhibition of mitochondrial Complex I (45). Thus, Cana treat-
ment may be acting, in part, by suppressing initiation and/or progression of age-associated cancers in UM-HET3 
mice, through SGLT1/2-dependent or -independent mechanisms, an idea to be explored in follow-up studies.
Osataphan et al. described numerous effects of  Cana on whole-body metabolism and signaling path-
ways in mice that may contribute to its beneficial effects on life span (27). In mice fed a high-fat diet to 
induce obesity, Cana reduced weight gain and blood glucose levels; and in mice fed either high-fat or normal 
chow, Cana enhanced fat and ketone body metabolism at the expense of  glucose utilization. Notably, the use 
of  alternative fuel sources such as fatty acids and ketones has been linked to the pro-longevity intervention 
calorie restriction (46). Cana suppressed hepatic TORC1 signaling, while increasing AMPK activity in this 
tissue; both effects are associated with life span extension in mice and other organisms (47). Cana treatment 
also increased serum levels of  FGF21, a peptide hormone that induces a shift from carbohydrate to lipid 
metabolism; FGF21 extends life span in mice when overexpressed (48). Since only male mice were examined 
in the Osataphan study (27), it is impossible to know whether any of  these Cana effects might show sexual 
dimorphism. Such data might help shed light on which among the pleiotropic effects of  Cana might be most 
relevant in promoting longer life, since the longevity benefit of  Cana is observed in male but not female mice.
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Combining COD and incidental lesion scores is a powerful approach to evaluate the effects of  a drug 
on progression of  age-related pathology over a life span. Male mice given Cana showed an increase in life 
span compared with controls, but with similar COD and incidental lesion scores, suggesting a delay in 
major and incidental lesion pathology associated with aging. A cross-sectional study, now under way, will 
produce specimens for histopathology study at a defined age, 22 months, at which the complications of  
selective death and variable postmortem interval have been greatly reduced. Such cross-sectional designs 
do not provide useful insights into possible drug effects on distribution of  COD diagnoses, but can provide 
a more finely grained look at drug effects on age-dependent changes in multiple tissues and organs (30). 
COD and incidental lesion scores can be used as a framework for establishing pathological endpoints (49) 
and can be combined with physiological performance tests to further validate the effectiveness and safety 
of  Cana or other drugs, either alone or in combination with other previously validated antiaging drugs.
Prospective clinical trials for Cana effects in humans might be enriched by inclusion of  endpoints that 
are signals of  age-dependent diseases and physiological change that are nominally independent from the 
effects of  the diseases, such as diabetes, for which the drug is prescribed. The dose used in this study pro-
vides 6 mg of  drug per kilogram of  mouse body weight per day, similar to the human therapeutic dose of  
100–300 mg/d for a 70 kg person. In parallel, secondary analysis of  databases that include long-term fol-
low-up on patients who are receiving Cana therapeutically might help to test the idea that this agent retards 
clinically important aspects of  multisystem aging in men or women or both. The ITP results using both 
Cana and acarbose suggest that many aspects of  age-related pathology, including those that lead to death 
in mice, could be sensitive to modulators of  peak glucose levels, rather than integrated measures of  average 
glucose values, with implications for both dietary and pharmacological avenues for prevention of  late-life 
diseases in humans. Delineation of  the mechanisms connecting Cana to slower aging, whether by effects 
on glucose or potentially through other pathways, are bound to have implications for our understanding of  
both mammalian aging and organ-specific pathophysiology.
Methods
Mice. These experiments used mice of the UM-HET3 genetically heterogeneous stock, produced by mating 
CByB6F1 mothers (JAX stock 100009), whose female parents are BALB/cByJ and whose male parents are 
C57BL/6J, to C3D2F1 fathers (JAX stock 100004), whose mothers are C3H/HeJ and whose fathers are 
DBA/2J. Each UM-HET3 mouse is genetically unique, but each shares 50% of its genetic endowment with 
every other UM-HET3 mouse, and the population thus consists of full sibs with respect to nuclear genes. Mice 
from second and subsequent litters were weaned into cages containing 3 male or 4 female mice and assigned 
to a control or treatment (Cana) group using a random number table. Mice at each test site were produced over 
a period of 6 months in 2016 in roughly equal monthly cohorts. The C2016 cohort also included mice treated 
with other agents, and the results of those studies will be reported separately. Mice in the Cana group received 
this agent at 180 mg/kg of chow, from 7 months of age; this dose is equivalent to 30 mg/kg mouse body weight 
for a 30 g mouse eating 5 g of food each day. Mice were weighed at 6, 12, 18, and 24 months but not subjected 
to any other manipulation. Cages were inspected daily, and deaths were noted. Mice that were deemed unlikely 
to live for more than another 24 hours, based on a symptom checklist, were euthanized for humane reasons, 
with the day of euthanasia taken as the best estimate of the date of natural death for statistical purposes. Mice 
removed from the study, either for fighting or for other technical reasons (e.g., chip ID dysfunction, escape, 
accidental injury), were treated as known to be alive on the day of removal but lost to follow-up at that point. 
These “removed” mice are included in the Kaplan-Meier survival calculations but not in calculations of medi-
an or 90th percentile survival age. Removed mice made up 4.8% of the original control group, and 3.8% of  
the Cana group. No other mice were censored from analyses. Details of husbandry conditions, such as cage 
changes, base diet, temperature, and light/dark cycle have been described extensively in other ITP reports (11, 
14). Specific pathogen–free status is assessed quarterly at each site using a combination of serological and 
molecular methods, and all such tests have been negative for each colony throughout the period reported.
Pathology. Each mouse found dead, or euthanized for humane reasons, was fixed as soon as possible. 
Incisions were made in the cranium, thorax, and abdomen, and the specimen then immersed in 10% neutral 
buffered formalin for storage at room temperature. Random samples from each of the 3 sites were later sent to 
the University of Washington Geropathology Research Program for gross inspection and for preparation of  
slides for histological examination. During gross examination and dissection, all obvious external and internal 
abnormalities were recorded. Tissues evaluated and collected for histological examination included decalcified 
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cross section of skull with brain (when intact), lung, mediastinal lymph node and fat, thymus (when able to 
identify), heart, kidney, adrenal glands, liver, spleen, pancreas, mesenteric fat and lymph node(s), thyroid gland, 
salivary glands, reproductive tract (consisting of uterus and ovaries for female mice and testis, epididymis, and 
seminal vesicles for male mice), and any additional lesions noted grossly. The gastrointestinal tract was inspect-
ed grossly but not routinely examined histologically owing to autolysis. Tissues were routinely processed and 
paraffin embedded, after which 4–5 μ sections were stained with H&E for histological assessment.
Tissues were examined for a single major abnormality such as a malignant tumor extensively involving 
an organ or involving multiple organs, severe inflammatory disease, or an end-stage degenerative process 
such as cardiomyopathy or glomerulonephropathy. If  such a process was identified, then this was consid-
ered the COD. In some mice, more than 1 severe abnormality was identified, and in these cases, death was 
attributed to 2 or more distinct lesions; these are listed in Results as “multiple” COD cases. If  the carcass 
was in generally good postmortem condition but no obvious COD was identified, the COD was listed as 
“unknown.” If  autolysis precluded critical histological evaluation of  tissues for COD, a designation of  
“autolysis” was made. Some incidental lesions were recorded as present or absent, and other incidental 
lesions were graded with a severity score.
HbA1C. Male and female mice at age 7 months were fed control or Cana diets for 7–8 months. These 
mice were not involved in the life span protocol. Blood was collected into EDTA-coated tubes from mice 
that were fasted for 6 hours starting at 8–9 am. Samples were shipped to UT, and HbA1c percentage for 
each whole blood sample was measured by immunoassay using a DCA Vantage Analyzer (Siemens Health-
ineers) according to the manufacturer’s instructions.
Measurement of  Cana in tissues. The liquid chromatography–tandem mass spectrometry system consisted 
of  a Shimadzu SIL 20A HT autosampler, LC-20AD pumps, and an AB Sciex API 4000 tandem mass spec-
trometer for plasma and an AB Sciex API 3200 tandem mass spectrometer for brain or kidney, both with 
turbo ion spray. The LC analytical column was an ACE Excel C18-PFP (75 × 3.0 mm, 3 μ) purchased from 
Mac-Mod Analytical, maintained at 25oC. Mobile phase A contained 0.1% formic acid dissolved in water. 
Mobile phase B contained 0.1% formic acid dissolved in 100% HPLC-grade acetonitrile. The flow rate of  
the mobile phase was 0.4 mL/min. Standard curves used Cana (MilliporeSigma). For plasma, calibrator 
samples used concentrations from 0.1–5 mg/mL, with Lidocaine D10 as an internal standard. The ratios 
of  Cana to lidocaine D10 peak areas for each unknown sample were compared against a linear regression 
of  the ratios obtained by the calibration samples to quantify Cana. The Cana transition was detected in pos-
itive mode at 445.3/267.2 Da. The Lidocaine D10 transition was detected at 245/96 Da. For kidney and 
brain, standard curves used a mixture of  male and female control kidney homogenate spiked with Cana 
over a range of  0.01–20 mg/mL, and the Cana expressed as nanograms per milligrams of  tissue.
The assessment of  food levels included measures of  within- and between-pellet homogeneity and drug 
stability. Mean levels in prepared food averaged 85% of  expected (nominal) concentration, with a range of  
53%–180% of  expected over 11 batches. Within- and between-pellet heterogeneity averaged 8%.
Metabolic analyses. Lean and fat body mass were assessed by a Bruker Minispec LF 90II NMR-based 
device. An i.p. GTT was performed on mice fasted for 3–4 hours. Animals were injected i.p. with D-glucose 
(2 g/kg) and blood glucose levels were measured at the indicated time points, with the preinjection blood 
sample used as a measure of  fasting glucose.
Statistics. The analytical plan was specified before the initiation of the study. Survival was evaluated using 
the log-rank test, stratified by site, conducted separately for male and female mice. P values are reported without 
adjustment for multiple comparisons. Secondary analyses of survival were conducted on data from each of the 
3 test sites. The WA test (28) was used to assess an analog of “maximal life span.” This method uses the Fisher’s 
exact test to contrast the proportions of mice alive or dead at the 90th percentile age of the joint (shared) survival 
table for control and Cana-treated mice together. The primary test employed the sum of live and dead mice tak-
en from each test site, separately for each sex, using the 90th percentile age for that site and sex. Drug effects on 
body weight were assessed by the 2-tailed Student’s t test, separately at each age for each sex, pooling across sites. 
Drug effects on specific inferred cause(s) of death, and on lesions scored as present or absent, were evaluated 
using the Fisher’s exact test, pooling across site and sex. Drug effects on lesions that were graded were assessed 
using the 2-tailed Student’s t test. HbA1C results were analyzed by 2-way ANOVA, with sex and drug (Cana) as 
the predictor variables. At time of publication, all survival, weight, and metabolic data reported in this paper will 
be made available in the Mouse Phenome Database (https://phenome.jax.org/projects/ITP1).
Study approval. All animal experiments were approved by the IACUC of TJL, UM, and UT.
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